# reload+after+2024-01-23 20:46:28.063246
address1§1020 Stony Hill Road
address2§Suite 300
city§Yardley
state§PA
zip§19067
country§United States
phone§267 364 3500
fax§267 395 2119
website§https://www.optinose.com
industry§Drug Manufacturers—Specialty & Generic
sector§Healthcare
longBusinessSummary§OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. OptiNose, Inc. has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail; and Orexia Therapeutics to develop, manufacture, import, and sale products containing orexin receptor agonist and/or orexin receptor positive modulator molecules for the treatment, diagnosis, or prevention of human diseases or conditions associated primarily with orexin receptor agonism and orexin receptor positive modulation. The company was founded in 2000 and is headquartered in Yardley, Pennsylvania.
fullTimeEmployees§141
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Ramy A. Mahmoud M.D., M.P.H.', 'age': 58, 'title': 'CEO & Director', 'yearBorn': 1965, 'fiscalYear': 2022, 'totalPay': 731587, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Michael F. Marino Esq.', 'age': 47, 'title': 'Chief Legal Officer & Corporate Secretary', 'yearBorn': 1976, 'fiscalYear': 2022, 'totalPay': 604237, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Anthony J. Krick', 'age': 42, 'title': 'Vice President & Chief Accounting Officer', 'yearBorn': 1981, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Jonathan  Neely', 'title': 'Vice President of Investor Relations & Business Operations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Karen E. Brophy', 'age': 60, 'title': 'Chief Human Resources Officer & VP of Human Resources', 'yearBorn': 1963, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Paul  Spence', 'age': 55, 'title': 'Chief Commercial Officer', 'yearBorn': 1968, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§8
boardRisk§5
compensationRisk§7
shareHolderRightsRisk§8
overallRisk§7
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§-0.268
priceToSalesTrailing12Months§1.8256277
currency§USD
dateShortInterest§1702598400
forwardEps§-0.26
pegRatio§-0.05
exchange§NMS
quoteType§EQUITY
shortName§OptiNose, Inc.
longName§OptiNose, Inc.
firstTradeDateEpochUtc§1507901400
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§9935cfef-8b2d-350a-a595-96d5fb99e4f0
gmtOffSetMilliseconds§-18000000
targetHighPrice§3.0
targetLowPrice§3.0
targetMeanPrice§3.0
targetMedianPrice§3.0
recommendationMean§1.7
recommendationKey§buy
numberOfAnalystOpinions§3
quickRatio§0.538
grossMargins§0.86824995
ebitdaMargins§-0.39148
trailingPegRatio§None
